Standard of Care CAR-T Cell Therapy

How CAR-T therapy works:

This short video explains how CAR-T therapy harnesses a patient's own cells to fight cancer.

Animation by Dr Maja Divjak

Current Treatments (standard of care and clinical trials)

Subsidised access to CAR-T therapy is available for eligible Australian patients with relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL), and eligible paediatric or young adult (up to 25 years) patients with relapsed or refractory Acute Lymphoblastic Leukaemia (ALL). 

The following therapies are currently offered as standard of care:

• Kymriah® (tisagenlecleucel)
  • Approved for:
    • Paediatric and adolescent ALL(post-transplant) or in second or later relapse
    • Adult relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy
• Yescarta® (Axicabtagene ciloleucel)
  • Approved for:
    • Adult relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
• Tecartus® (brexucabtagene autoleucel)
  • Approved for:
    • Adult relapsed or refractory mantle cell lymphoma (MCL), who have received two or more lines of therapy, including a BTK inhibitor (unless ineligible or intolerant to treatment with a BTK inhibitor)

Further CAR-T therapies for the treatment of additional cancers are under review for approval in 2023 and beyond.

The CoE CIT hosts in a national, weekly CAR-T patient prioritisation meeting where new patient referrals are discussed nationally to ensure fair and equitable access to standard of care CAR-T cell therapies, as well as available clinical trials.

How do I access CAR-T for my patients?

Email: [email protected]